<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Module 9: Airway, Sedation & Procedural Drugs</title>
    <style>
        /* EXACT STYLES FROM MODULE 6 */
        body {
            font-family: 'Calibri', 'Segoe UI', sans-serif;
            line-height: 1.5;
            color: #2c3e50;
            margin: 2cm;
            background-color: #ffffff;
            counter-reset: chapter section figure table;
        }
        
        h1 {
            font-size: 28pt;
            font-weight: bold;
            color: #1a5276;
            text-align: center;
            border-bottom: 3px double #3498db;
            padding-bottom: 10px;
            margin-bottom: 30px;
        }
        
        h2 {
            font-size: 18pt;
            font-weight: bold;
            color: #ffffff;
            background-color: #2980b9;
            padding: 10px 15px;
            border-radius: 5px;
            margin-top: 30px;
            page-break-after: avoid;
        }
        
        h3 {
            font-size: 14pt;
            font-weight: bold;
            color: #154360;
            margin-top: 20px;
            margin-bottom: 10px;
            page-break-after: avoid;
        }
        
        h4 {
            font-size: 12.5pt;
            font-weight: bold;
            color: #21618c;
            margin-top: 15px;
            margin-bottom: 8px;
        }
        
        .module-title {
            font-size: 20pt;
            font-weight: bold;
            color: #21618c;
            margin-top: 40px;
            border-left: 6px solid #3498db;
            padding-left: 15px;
        }
        
        .chapter-number {
            background-color: #3498db;
            color: white;
            padding: 5px 12px;
            border-radius: 50%;
            display: inline-block;
            margin-right: 10px;
            font-weight: bold;
        }
        
        /* Lists */
        ul, ol {
            padding-left: 1.5em;
            margin-bottom: 1em;
        }
        
        li {
            margin-bottom: 8px;
            font-size: 11.5pt;
        }
        
        .sub-list {
            list-style-type: lower-alpha;
            padding-left: 2.5em;
        }
        
        .drug-list {
            columns: 2;
            column-gap: 50px;
            margin-top: 15px;
        }
        
        .drug-list li {
            break-inside: avoid;
        }
        
        /* Special Boxes */
        .study-format {
            background-color: #e8f4fc;
            border: 1px solid #aed6f1;
            border-left: 6px solid #2e86c1;
            padding: 20px;
            margin-top: 30px;
            page-break-inside: avoid;
        }
        
        .clinical-pearl {
            background-color: #fff3cd;
            border: 1px solid #ffeaa7;
            border-left: 6px solid #fdcb6e;
            padding: 15px;
            margin: 15px 0;
            border-radius: 0 5px 5px 0;
        }
        
        .warning-box {
            background-color: #f8d7da;
            border: 1px solid #f5c6cb;
            border-left: 6px solid #e74c3c;
            padding: 15px;
            margin: 15px 0;
            border-radius: 0 5px 5px 0;
        }
        
        .definition-box {
            background-color: #d1ecf1;
            border: 1px solid #bee5eb;
            border-left: 6px solid #17a2b8;
            padding: 15px;
            margin: 15px 0;
            border-radius: 0 5px 5px 0;
        }
        
        /* Tables */
        .comparison-table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            font-size: 11pt;
        }
        
        .comparison-table th {
            background-color: #2980b9;
            color: white;
            padding: 10px;
            text-align: left;
            border: 1px solid #1a5276;
        }
        
        .comparison-table td {
            padding: 10px;
            border: 1px solid #ddd;
            vertical-align: top;
        }
        
        .comparison-table tr:nth-child(even) {
            background-color: #f8f9fa;
        }
        
        /* Page Layout */
        .page-break {
            page-break-before: always;
        }
        
        .footer-note {
            font-size: 9pt;
            color: #7f8c8d;
            text-align: center;
            margin-top: 30px;
            border-top: 1px solid #ecf0f1;
            padding-top: 10px;
        }
        
        /* Drug Template - EXACT MATCH */
        .drug-template {
            background-color: #f9f9f9;
            border: 1px solid #ddd;
            padding: 20px;
            margin: 25px 0;
            border-radius: 5px;
            page-break-inside: avoid;
        }
        
        .drug-template h4 {
            color: #2c3e50;
            border-bottom: 2px solid #3498db;
            padding-bottom: 5px;
            margin-top: 0;
        }
        
        .template-section {
            margin-bottom: 15px;
        }
        
        .template-label {
            font-weight: bold;
            color: #2980b9;
            display: inline-block;
            width: 180px;
        }
        
        /* Emoji Styling */
        .emoji {
            font-size: 1.2em;
        }
        
        /* Print Specific */
        @media print {
            body {
                margin: 1.5cm;
                font-size: 11pt;
            }
            
            .page-break {
                page-break-before: always;
            }
            
            .no-print {
                display: none;
            }
            
            a {
                color: black;
                text-decoration: none;
            }
        }
        
        /* Learning Objectives */
        .learning-objectives {
            background-color: #e8f6f3;
            border: 1px solid #a2d9ce;
            padding: 15px;
            margin: 20px 0;
            border-radius: 5px;
        }
        
        .objective-list {
            list-style-type: none;
            padding-left: 0;
        }
        
        .objective-list li:before {
            content: "‚úì ";
            color: #27ae60;
            font-weight: bold;
            margin-right: 10px;
        }
        
        /* Module 9 Specific Colors */
        .ketamine-purple {
            color: #8e44ad;
            font-weight: bold;
        }
        
        .propofol-white {
            color: #2c3e50;
            font-weight: bold;
        }
        
        .etomidate-orange {
            color: #e67e22;
            font-weight: bold;
        }
        
        .succinylcholine-red {
            color: #e74c3c;
            font-weight: bold;
        }
        
        .rocuronium-blue {
            color: #2980b9;
            font-weight: bold;
        }
        
        .lidocaine-green {
            color: #27ae60;
            font-weight: bold;
        }
        
        /* Module 9 Specific Boxes */
        .airway-alert {
            background-color: #f2d7d5;
            border: 2px solid #c0392b;
            padding: 20px;
            margin: 20px 0;
            border-radius: 8px;
            font-weight: bold;
        }
        
        .rapid-sequence-box {
            background-color: #2c3e50;
            border: 2px solid #34495e;
            color: white;
            padding: 20px;
            margin: 20px 0;
            border-radius: 8px;
        }
        
        .sedation-box {
            background-color: #d4e6f1;
            border: 2px solid #21618c;
            color: #1a5276;
            padding: 20px;
            margin: 20px 0;
            border-radius: 8px;
        }
        
        .neuromuscular-box {
            background-color: #fdebd0;
            border: 2px solid #f39c12;
            padding: 20px;
            margin: 20px 0;
            border-radius: 8px;
        }
        
        .local-anesthetic-box {
            background-color: #e8f8f5;
            border: 2px solid #45b39d;
            padding: 15px;
            margin: 15px 0;
            border-radius: 5px;
        }
        
        .difficult-airway {
            background-color: #f4ecf7;
            border: 2px solid #8e44ad;
            padding: 15px;
            margin: 15px 0;
            border-radius: 5px;
        }
    </style>
</head>
<body>

<div class="module-title">
    <span class="emoji">üü™</span> MODULE 9: AIRWAY, SEDATION & PROCEDURAL DRUGS (HIGH-YIELD)
    <div style="font-size: 12pt; font-weight: normal; font-style: italic; color: #7f8c8d;">
        (Ketamine, Propofol, Etomidate, Succinylcholine, Rocuronium, Lidocaine)
    </div>
</div>

<div class="learning-objectives">
    <h3 style="color: #148f77; margin-top: 0;">üìñ Learning Objectives</h3>
    <ul class="objective-list">
        <li>Master Rapid Sequence Intubation (RSI) pharmacology and sequencing</li>
        <li>Understand induction agent selection based on hemodynamic status</li>
        <li>Learn neuromuscular blocker pharmacology and reversal</li>
        <li>Recognize and manage local anesthetic systemic toxicity (LAST)</li>
        <li>Apply procedural sedation and analgesia (PSA) protocols safely</li>
        <li>Manage difficult airway scenarios pharmacologically</li>
        <li>Understand monitoring requirements for sedative agents</li>
        <li>Apply knowledge to common emergency airway scenarios</li>
    </ul>
</div>

<!-- INTRODUCTION -->
<h2><span class="chapter-number">0</span> Introduction: Emergency Airway Pharmacology</h2>

<div class="warning-box">
    <strong>‚ö†Ô∏è AIRWAY MANAGEMENT IS A HIGH-RISK PROCEDURE:</strong> Failed intubation occurs in 1:100-1:200 emergency intubations. Have a plan A, B, C, and D. Know your rescue devices. Pre-oxygenate for 3-5 minutes. Have suction ready. Prepare for the worst, hope for the best.
</div>

<div class="clinical-pearl">
    <strong>üß† Core Concept:</strong> Rapid Sequence Intubation (RSI) follows 7 Ps:<br>
    1. <strong class="ketamine-purple">Preparation</strong> (equipment, drugs, personnel, plan)<br>
    2. <strong class="ketamine-purple">Pre-oxygenation</strong> (3-5 minutes, 100% O‚ÇÇ, NIV if needed)<br>
    3. <strong class="ketamine-purple">Pre-treatment</strong> (optional: lidocaine, opioids, atropine)<br>
    4. <strong class="ketamine-purple">Paralysis with induction</strong> (sedative + neuromuscular blocker)<br>
    5. <strong class="ketamine-purple">Protection and positioning</strong> (cricoid pressure, sniffing position)<br>
    6. <strong class="ketamine-purple">Placement with proof</strong> (intubate, confirm with EtCO‚ÇÇ, CXR)<br>
    7. <strong class="ketamine-purple">Post-intubation management</strong> (sedation, ventilation, monitoring)<br>
    This module focuses on the pharmacological components you MUST know.
</div>

<!-- STUDY FORMAT -->
<div class="study-format">
    <h3><span class="emoji">üìã</span> HOW WE WILL STUDY EACH DRUG (FIXED TEMPLATE)</h3>
    <p><strong>For every drug, we will follow ONE SAME FORMAT:</strong></p>
    <ol>
        <li><strong>Drug class</strong> - Pharmacological category</li>
        <li><strong>Mechanism of action</strong> - How it works at receptor level</li>
        <li><strong>Indications</strong> - Specific airway/sedation scenarios</li>
        <li><strong>Contraindications</strong> - Absolute and relative contraindications</li>
        <li><strong>Adult dose</strong> - Exact emergency dosing</li>
        <li><strong>Pediatric dose</strong> - Weight-based calculations</li>
        <li><strong>Route & preparation</strong> - How to prepare and administer safely</li>
        <li><strong>Side effects</strong> - Common, expected effects</li>
        <li><strong>Adverse effects / ADR</strong> - Serious reactions and risks</li>
        <li><strong>Drug interactions</strong> - Important combinations to avoid/watch</li>
        <li><strong>Emergency pearls</strong> - Clinical tips, exam favorites, practical wisdom</li>
    </ol>
</div>

<!-- CHAPTER 1: RAPID SEQUENCE INTUBATION (RSI) PROTOCOL -->
<h2><span class="chapter-number">1</span> Rapid Sequence Intubation (RSI) Protocol</h2>

<div class="definition-box">
    <strong>Rapid Sequence Intubation (RSI):</strong> A systematic approach to emergency airway management that involves simultaneous administration of a sedative (induction agent) and a neuromuscular blocking agent to rapidly induce unconsciousness and paralysis, minimizing the time between loss of protective reflexes and securing the airway.
</div>

<h3>1.1 The RSI Sequence (Timeline)</h3>

<table class="comparison-table">
    <thead>
        <tr>
            <th style="width: 15%;">Time</th>
            <th>Step</th>
            <th>Action</th>
            <th>Drugs (if applicable)</th>
        </tr>
    </thead>
    <tbody>
        <tr>
            <td><strong>T-5 min</strong></td>
            <td>Preparation</td>
            <td>Equipment check, drug preparation, team briefing, plan B/C</td>
            <td>None</td>
        </tr>
        <tr>
            <td><strong>T-3 min</strong></td>
            <td>Pre-oxygenation</td>
            <td>100% O‚ÇÇ via NRB or BVM, consider NIV if hypoxic</td>
            <td>None</td>
        </tr>
        <tr>
            <td><strong>T-2 min</strong></td>
            <td>Pre-treatment (optional)</td>
            <td>Consider for specific indications (ICP, asthma, pediatric)</td>
            <td>Lidocaine, fentanyl, atropine</td>
        </tr>
        <tr>
            <td><strong>T=0</strong></td>
            <td>Paralysis with induction</td>
            <td>Give induction agent immediately followed by NMBA</td>
            <td>Etomidate/ketamine/propofol + Succinylcholine/rocuronium</td>
        </tr>
        <tr>
            <td><strong>T+30 sec</strong></td>
            <td>Protection/positioning</td>
            <td>Cricoid pressure, optimal positioning, apnoeic oxygenation</td>
            <td>None</td>
        </tr>
        <tr>
            <td><strong>T+45-60 sec</strong></td>
            <td>Laryngoscopy</td>
            <td>Intubate when fully paralyzed (no fasciculations/full relaxation)</td>
            <td>None</td>
        </tr>
        <tr>
            <td><strong>T+1-2 min</strong></td>
            <td>Confirmation</td>
            <td>EtCO‚ÇÇ, chest rise, auscultation, CXR</td>
            <td>None</td>
        </tr>
        <tr>
            <td><strong>T+2-5 min</strong></td>
            <td>Post-intubation</td>
            <td>Secure tube, start sedation/analgesia, ventilate appropriately</td>
            <td>Midazolam, fentanyl, propofol infusion</td>
        </tr>
    </tbody>
</table>

<div class="rapid-sequence-box">
    <strong>üö® RAPID SEQUENCE INTUBATION - DRUG SELECTION BY SCENARIO:</strong><br>
    <br>
    <strong>üë®‚Äç‚öïÔ∏è HEMODYNAMICALLY STABLE ADULT:</strong><br>
    ‚Ä¢ Induction: <strong class="etomidate-orange">Etomidate 0.3 mg/kg</strong> (20 mg typical)<br>
    ‚Ä¢ Paralysis: <strong class="succinylcholine-red">Succinylcholine 1.5 mg/kg</strong> (100 mg typical) OR <strong class="rocuronium-blue">Rocuronium 1.2 mg/kg</strong> (100 mg typical)<br>
    <br>
    <strong>üíî HYPOTENSIVE/SEPTIC SHOCK:</strong><br>
    ‚Ä¢ Induction: <strong class="ketamine-purple">Ketamine 1-2 mg/kg</strong> (preserves BP)<br>
    ‚Ä¢ Paralysis: <strong class="rocuronium-blue">Rocuronium 1.2 mg/kg</strong> (avoid succinylcholine if hyperkalemia risk)<br>
    <br>
    <strong>üß† HEAD INJURY/INCREASED ICP:</strong><br>
    ‚Ä¢ Pre-treatment: <strong class="lidocaine-green">Lidocaine 1.5 mg/kg</strong> IV 90 sec before induction<br>
    ‚Ä¢ Induction: <strong class="etomidate-orange">Etomidate 0.3 mg/kg</strong> + <strong class="lidocaine-green">Fentanyl 1-3 mcg/kg</strong><br>
    ‚Ä¢ Paralysis: <strong class="succinylcholine-red">Succinylcholine 1.5 mg/kg</strong> (rapid onset)<br>
    <br>
    <strong>ü´Å ASTHMA/STATUS ASTHMATICUS:</strong><br>
    ‚Ä¢ Pre-treatment: <strong class="lidocaine-green">Lidocaine 1.5 mg/kg</strong> IV<br>
    ‚Ä¢ Induction: <strong class="ketamine-purple">Ketamine 1-2 mg/kg</strong> (bronchodilation)<br>
    ‚Ä¢ Paralysis: <strong class="rocuronium-blue">Rocuronium 1.2 mg/kg</strong> (avoid histamine release)<br>
    <br>
    <strong>üë∂ PEDIATRIC (<10 years):</strong><br>
    ‚Ä¢ Pre-treatment: <strong class="lidocaine-green">Atropine 0.02 mg/kg</strong> (min 0.1 mg) if <1 year or giving succinylcholine<br>
    ‚Ä¢ Induction: <strong class="ketamine-purple">Ketamine 1-2 mg/kg</strong><br>
    ‚Ä¢ Paralysis: <strong class="succinylcholine-red">Succinylcholine 1-2 mg/kg</strong> (if no contraindications)<br>
</div>

<!-- CHAPTER 2: DRUG 1 - KETAMINE -->
<div class="page-break"></div>
<h2><span class="chapter-number">2</span> Core Drug 1: Ketamine</h2>

<div class="drug-template">
    <h4>KETAMINE - DISSOCIATIVE ANESTHETIC WITH ANALGESIC PROPERTIES</h4>
    
    <div class="template-section">
        <span class="template-label">Drug class:</span> Dissociative anesthetic, NMDA receptor antagonist
    </div>
    
    <div class="template-section">
        <span class="template-label">Mechanism of action:</span> 
        ‚Ä¢ Non-competitive antagonist at NMDA (N-methyl-D-aspartate) receptors<br>
        ‚Ä¢ Produces "dissociative anesthesia" - patient appears awake but disconnected<br>
        ‚Ä¢ Maintains protective airway reflexes better than other induction agents<br>
        ‚Ä¢ Sympathomimetic effects - increases HR, BP, CO via catecholamine release<br>
        ‚Ä¢ Direct myocardial depressant (unmasked in catecholamine-depleted states)<br>
        ‚Ä¢ Bronchodilator (useful in asthma/status asthmaticus)<br>
        ‚Ä¢ Analgesic at sub-anesthetic doses (0.1-0.5 mg/kg)
    </div>
    
    <div class="template-section">
        <span class="template-label">Indications:</span>
        ‚Ä¢ Induction agent for RSI (especially in hypotensive, asthmatic patients)<br>
        ‚Ä¢ Procedural sedation and analgesia (PSA) for painful procedures<br>
        ‚Ä¢ Sedation in agitated patients (Excited Delirium Syndrome)<br>
        ‚Ä¢ Refractory status epilepticus (adjunctive therapy)<br>
        ‚Ä¢ Analgesia for trauma, burns, dressing changes<br>
        ‚Ä¢ Bronchospasm (asthma/COPD exacerbation refractory to standard therapy)<br>
        ‚Ä¢ Depression treatment (off-label, sub-anesthetic doses)<br>
        ‚Ä¢ Field anesthesia in resource-limited settings
    </div>
    
    <div class="template-section">
        <span class="template-label">Contraindications:</span>
        ‚Ä¢ Known hypersensitivity to ketamine<br>
        ‚Ä¢ Significant ischemic heart disease (increases myocardial oxygen demand)<br>
        ‚Ä¢ Uncontrolled hypertension (exacerbates hypertension)<br>
        ‚Ä¢ Elevated intracranial pressure (increases cerebral metabolic rate and ICP)<br>
        ‚Ä¢ Active psychosis/schizophrenia (may exacerbate symptoms)<br>
        ‚Ä¢ Thyroid disorder (may precipitate thyroid storm)<br>
        ‚Ä¢ Porphyria (relative contraindication)<br>
        ‚Ä¢ Ocular injuries/glaucoma (increases intraocular pressure)
    </div>
    
    <div class="template-section">
        <span class="template-label">Adult dose:</span>
        ‚Ä¢ <strong class="ketamine-purple">RSI induction:</strong> 1-2 mg/kg IV (typical 100-200 mg)<br>
        ‚Ä¢ <strong class="ketamine-purple">IM induction:</strong> 4-5 mg/kg IM (if no IV access)<br>
        ‚Ä¢ <strong class="ketamine-purple">Procedural sedation:</strong> 0.5-1 mg/kg IV, repeat 0.25-0.5 mg/kg as needed<br>
        ‚Ä¢ <strong class="ketamine-purple">Analgesia:</strong> 0.1-0.5 mg/kg IV/IM q30-60min<br>
        ‚Ä¢ <strong class="ketamine-purple">Infusion for sedation:</strong> 0.1-0.5 mg/kg/hr after loading dose<br>
        ‚Ä¢ <strong class="ketamine-purple">Status epilepticus:</strong> 1-2 mg/kg IV load, then 1-5 mg/kg/hr infusion<br>
        ‚Ä¢ <strong class="ketamine-purple">Max single dose:</strong> 4 mg/kg IM, 2 mg/kg IV
    </div>
    
    <div class="template-section">
        <span class="template-label">Pediatric dose:</span>
        ‚Ä¢ <strong class="ketamine-purple">RSI induction:</strong> 1-2 mg/kg IV<br>
        ‚Ä¢ <strong class="ketamine-purple">IM induction:</strong> 4-5 mg/kg IM<br>
        ‚Ä¢ <strong class="ketamine-purple">Procedural sedation:</strong> 1-2 mg/kg IV, 3-4 mg/kg IM<br>
        ‚Ä¢ <strong class="ketamine-purple">Analgesia:</strong> 0.1-0.5 mg/kg IV/IM<br>
        ‚Ä¢ <strong class="ketamine-purple">Neonates/infants:</strong> Use lower doses (0.5-1 mg/kg IV)<br>
        ‚Ä¢ <strong class="ketamine-purple">With atropine/midazolam:</strong> Often co-administered to reduce secretions/emergence reactions
    </div>
    
    <div class="template-section">
        <span class="template-label">Route & preparation:</span>
        ‚Ä¢ <strong class="ketamine-purple">Routes:</strong> IV (preferred), IM, oral, intranasal, rectal<br>
        ‚Ä¢ <strong class="ketamine-purple">Preparation:</strong> 10 mg/mL (50 mg/5 mL), 50 mg/mL (500 mg/10 mL), 100 mg/mL<br>
        ‚Ä¢ <strong class="ketamine-purple">For IV push:</strong> Give undiluted over 30-60 seconds<br>
        ‚Ä¢ <strong class="ketamine-purple">For infusion:</strong> Dilute to 1-2 mg/mL in NS or D5W<br>
        ‚Ä¢ <strong class="ketamine-purple">IM administration:</strong> Deep IM injection, onset 3-5 minutes<br>
        ‚Ä¢ <strong class="ketamine-purple">Compatibility:</strong> Compatible with most IV solutions, NOT with barbiturates (precipitate)
    </div>
    
    <div class="template-section">
        <span class="template-label">Side effects:</span>
        ‚Ä¢ Emergence reactions (vivid dreams, hallucinations) - 10-30%<br>
        ‚Ä¢ Increased secretions (treat with atropine/glycopyrrolate)<br>
        ‚Ä¢ Nystagmus (dose-related)<br>
        ‚Ä¢ Hypertension, tachycardia (sympathomimetic effects)<br>
        ‚Ä¢ Nausea, vomiting (especially with movement during recovery)<br>
        ‚Ä¢ Increased intraocular pressure (transient)<br>
        ‚Ä¢ Transient apnea (with rapid IV administration)
    </div>
    
    <div class="template-section">
        <span class="template-label">Adverse effects / ADR:</span>
        ‚Ä¢ Laryngospasm (1-2%, especially with upper airway procedures)<br>
        ‚Ä¢ Emergence delirium (agitation, confusion - reduced by co-administering midazolam)<br>
        ‚Ä¢ Myocardial depression (in catecholamine-depleted patients - sepsis, heart failure)<br>
        ‚Ä¢ Increased intracranial pressure (controversial - avoid in known elevated ICP)<br>
        ‚Ä¢ Psychotomimetic effects (especially in psychiatric patients)<br>
        ‚Ä¢ Aspiration (rare - protective reflexes relatively preserved)<br>
        ‚Ä¢ Allergic reactions (rare)
    </div>
    
    <div class="template-section">
        <span class="template-label">Drug interactions:</span>
        ‚Ä¢ <strong class="ketamine-purple">Benzodiazepines:</strong> Reduce emergence reactions but prolong recovery<br>
        ‚Ä¢ <strong class="ketamine-purple">Theophylline/aminophylline:</strong> Increased seizure risk<br>
        ‚Ä¢ <strong class="ketamine-purple">Sympathomimetics:</strong> Additive cardiovascular effects<br>
        ‚Ä¢ <strong class="ketamine-purple">Volatile anesthetics:</strong> Prolongs recovery<br>
        ‚Ä¢ <strong class="ketamine-purple">NMBAs:</strong> Potentiates neuromuscular blockade<br>
        ‚Ä¢ <strong class="ketamine-purple">Thyroid hormones:</strong> May precipitate thyroid storm
    </div>
    
    <div class="template-section">
        <span class="template-label">Emergency pearls:</span>
        ‚Ä¢ <strong class="ketamine-purple">"Hemodynamically friendly":</strong> First choice for hypotensive/hemodynamically unstable patients<br>
        ‚Ä¢ <strong class="ketamine-purple">Bronchodilator:</strong> Only induction agent with bronchodilating properties - use in asthma<br>
        ‚Ä¢ <strong class="ketamine-purple">Emergence reactions:</strong> Prevent with midazolam 0.02-0.04 mg/kg IV 5 min before ketamine<br>
        ‚Ä¢ <strong class="ketamine-purple">Secretions:</strong> Pre-treat with atropine 0.01-0.02 mg/kg IV (especially pediatric)<br>
        ‚Ä¢ <strong class="ketamine-purple">"Kitty Magic":</strong> Ketamine 4 mg/kg IM + midazolam 0.05 mg/kg IM for agitated delirium<br>
        ‚Ä¢ <strong class="ketamine-purple">Catecholamine-depleted:</strong> Can cause myocardial depression in septic/critically ill patients<br>
        ‚Ä¢ <strong class="ketamine-purple">Analgesic properties:</strong> Provides analgesia at sub-anesthetic doses (0.1-0.5 mg/kg)<br>
        ‚Ä¢ <strong class="ketamine-purple">"Cannot intubate, cannot ventilate":</strong> Consider ketamine to maintain spontaneous respirations
    </div>
</div>

<!-- CHAPTER 3: DRUG 2 - PROPOFOL -->
<div class="page-break"></div>
<h2><span class="chapter-number">3</span> Core Drug 2: Propofol</h2>

<div class="drug-template">
    <h4>PROPOFOL - ULTRASHORT-ACTING SEDATIVE-HYPNOTIC</h4>
    
    <div class="template-section">
        <span class="template-label">Drug class:</span> Alkylphenol, GABA-A receptor agonist
    </div>
    
    <div class="template-section">
        <span class="template-label">Mechanism of action:</span> 
        ‚Ä¢ Potentiates GABA-A receptor activity ‚Üí increased chloride conductance ‚Üí neuronal hyperpolarization<br>
        ‚Ä¢ No analgesic properties (pure sedative-hypnotic)<br>
        ‚Ä¢ Rapid onset (30-60 seconds) due to high lipid solubility<br>
        ‚Ä¢ Rapid redistribution and metabolism ‚Üí short duration (5-10 minutes single dose)<br>
        ‚Ä¢ Antiemetic properties (useful for procedural sedation)<br>
        ‚Ä¢ Decreases cerebral metabolic rate and intracranial pressure<br>
        ‚Ä¢ Myocardial depressant and vasodilator ‚Üí hypotension common
    </div>
    
    <div class="template-section">
        <span class="template-label">Indications:</span>
        ‚Ä¢ Induction agent for RSI (in hemodynamically stable patients)<br>
        ‚Ä¢ Procedural sedation (endoscopy, cardioversion, reduction of dislocations)<br>
        ‚Ä¢ Maintenance of sedation in mechanically ventilated patients (ICU)<br>
        ‚Ä¢ Refractory status epilepticus (high-dose infusion)<br>
        ‚Ä¢ Antiemetic (subhypnotic doses: 10-20 mg IV)<br>
        ‚Ä¢ Treatment of refractory intracranial hypertension<br>
        ‚Ä¢ Sedation for imaging studies<br>
        ‚Ä¢ Post-operative nausea and vomiting prophylaxis
    </div>
    
    <div class="template-section">
        <span class="template-label">Contraindications:</span>
        ‚Ä¢ Known hypersensitivity to propofol, eggs, or soybean oil (lipid emulsion base)<br>
        ‚Ä¢ Hemodynamic instability/shock (significant hypotension risk)<br>
        ‚Ä¢ Increased intracranial pressure without adequate MAP (risk of cerebral hypoperfusion)<br>
        ‚Ä¢ Egg or soybean allergy (contains egg lecithin and soybean oil)<br>
        ‚Ä¢ Disorders of fat metabolism (lipid emulsion)<br>
        ‚Ä¢ Pregnancy (Category B, but generally avoided in 1st trimester)<br>
        ‚Ä¢ Not for prolonged sedation in children (risk of propofol infusion syndrome)
    </div>
    
    <div class="template-section">
        <span class="template-label">Adult dose:</span>
        ‚Ä¢ <strong class="propofol-white">RSI induction:</strong> 1.5-2.5 mg/kg IV (typical 100-200 mg)<br>
        ‚Ä¢ <strong class="propofol-white">Procedural sedation:</strong> 0.5-1 mg/kg IV, then 0.25-0.5 mg/kg q3-5min as needed<br>
        ‚Ä¢ <strong class="propofol-white">Sedation infusion:</strong> 5-80 mcg/kg/min (0.3-4.8 mg/kg/hr)<br>
        ‚Ä¢ <strong class="propofol-white">ICU sedation:</strong> 5-50 mcg/kg/min (0.3-3 mg/kg/hr)<br>
        ‚Ä¢ <strong class="propofol-white">Refractory status epilepticus:</strong> 1-2 mg/kg bolus, then 1-15 mg/kg/hr infusion<br>
        ‚Ä¢ <strong class="propofol-white">Antiemetic:</strong> 10-20 mg IV single dose<br>
        ‚Ä¢ <strong class="propofol-white">Elderly/debilitated:</strong> Reduce dose by 50% (0.5-1 mg/kg)
    </div>
    
    <div class="template-section">
        <span class="template-label">Pediatric dose:</span>
        ‚Ä¢ <strong class="propofol-white">RSI induction:</strong> 2-3 mg/kg IV (higher mg/kg than adults)<br>
        ‚Ä¢ <strong class="propofol-white">Procedural sedation:</strong> 1-2 mg/kg IV, then 0.5-1 mg/kg q2-3min as needed<br>
        ‚Ä¢ <strong class="propofol-white">Sedation infusion:</strong> 25-200 mcg/kg/min (1.5-12 mg/kg/hr) - SHORT TERM ONLY<br>
        ‚Ä¢ <strong class="propofol-white">NOT for prolonged ICU sedation</strong> in children (propofol infusion syndrome risk)<br>
        ‚Ä¢ <strong class="propofol-white">Neonates/infants:</strong> Use with extreme caution, lower doses<br>
        ‚Ä¢ <strong class="propofol-white">Max infusion duration:</strong> <48 hours in children, <4 mg/kg/hr
    </div>
    
    <div class="template-section">
        <span class="template-label">Route & preparation:</span>
        ‚Ä¢ <strong class="propofol-white">Routes:</strong> IV only (painful on injection)<br>
        ‚Ä¢ <strong class="propofol-white">Preparation:</strong> 10 mg/mL emulsion (20 mL = 200 mg, 50 mL = 500 mg, 100 mL = 1000 mg)<br>
        ‚Ä¢ <strong class="propofol-white">For IV push:</strong> Give undiluted over 30-60 seconds<br>
        ‚Ä¢ <strong class="propofol-white">For infusion:</strong> Use undiluted via syringe pump or infusion pump<br>
        ‚Ä¢ <strong class="propofol-white">Pain on injection:</strong> Can mix with lidocaine (1 mL 1% lidocaine per 10 mL propofol)<br>
        ‚Ä¢ <strong class="propofol-white">Aseptic technique:</strong> Supports bacterial growth - use within 6-12 hours of opening<br>
        ‚Ä¢ <strong class="propofol-white">Storage:</strong> Room temperature, protect from light, do not freeze
    </div>
    
    <div class="template-section">
        <span class="template-label">Side effects:</span>
        ‚Ä¢ Dose-dependent hypotension (20-30% of patients)<br>
        ‚Ä¢ Respiratory depression/apnea (especially with rapid administration)<br>
        ‚Ä¢ Pain on injection (30-40%, reduced by lidocaine or larger vein)<br>
        ‚Ä¢ Myoclonus (involuntary muscle movements)<br>
        ‚Ä¢ Hiccups, cough<br>
        ‚Ä¢ Hypertriglyceridemia (with prolonged infusion)<br>
        ‚Ä¢ Green urine (phenol metabolite)
    </div>
    
    <div class="template-section">
        <span class="template-label">Adverse effects / ADR:</span>
        ‚Ä¢ Propofol Infusion Syndrome (PRIS) - fatal metabolic acidosis, rhabdomyolysis, cardiac failure<br>
        ‚Ä¢ Severe hypotension/bradycardia/cardiac arrest<br>
        ‚Ä¢ Anaphylaxis (especially in egg/soy allergy)<br>
        ‚Ä¢ Pancreatitis (with prolonged use)<br>
        ‚Ä¢ Seizures (paradoxical, rare)<br>
        ‚Ä¢ Infections (if contamination occurs - supports bacterial growth)<br>
        ‚Ä¢ Hyperkalemia (in PRIS)
    </div>
    
    <div class="template-section">
        <span class="template-label">Drug interactions:</span>
        ‚Ä¢ <strong class="propofol-white">Other CNS depressants:</strong> Synergistic effects (opioids, benzodiazepines, alcohol)<br>
        ‚Ä¢ <strong class="propofol-white">Opioids:</strong> Potentiates respiratory depression and hypotension<br>
        ‚Ä¢ <strong class="propofol-white">Benzodiazepines:</strong> Potentiates sedation, increases apnea risk<br>
        ‚Ä¢ <strong class="propofol-white">Inhalational anesthetics:</strong> Additive effects<br>
        ‚Ä¢ <strong class="propofol-white">Calcium channel blockers:</strong> Increased hypotension/bradycardia<br>
        ‚Ä¢ <strong class="propofol-white">Theophylline:</strong> May antagonize sedative effects
    </div>
    
    <div class="template-section">
        <span class="template-label">Emergency pearls:</span>
        ‚Ä¢ <strong class="propofol-white">"Milk of Amnesia":</strong> White emulsion appearance<br>
        ‚Ä¢ <strong class="propofol-white">Rapid onset/offset:</strong> Ideal for short procedures (5-10 minute duration single dose)<br>
        ‚Ä¢ <strong class="propofol-white">Hypotension warning:</strong> Give slowly over 60 seconds, have fluids/vasopressors ready<br>
        ‚Ä¢ <strong class="propofol-white">No analgesic properties:</strong> Must co-administer analgesic for painful procedures<br>
        ‚Ä¢ <strong class="propofol-white">Propofol Infusion Syndrome (PRIS):</strong> Risk with >4-5 mg/kg/hr for >48h, especially in children<br>
        ‚Ä¢ <strong class="propofol-white">Pain on injection:</strong> Pretreat with lidocaine or use larger vein (antecubital)<br>
        ‚Ä¢ <strong class="propofol-white">Egg allergy:</strong> Contains egg lecithin - contraindicated in severe egg allergy<br>
        ‚Ä¢ <strong class="propofol-white">Caloric content:</strong> 1.1 kcal/mL (from lipid emulsion) - consider in long-term infusions
    </div>
</div>

<!-- CHAPTER 4: DRUG 3 - ETOMIDATE -->
<div class="page-break"></div>
<h2><span class="chapter-number">4</span> Core Drug 3: Etomidate</h2>

<div class="drug-template">
    <h4>ETOMIDATE - HEMODYNAMICALLY NEUTRAL INDUCTION AGENT</h4>
    
    <div class="template-section">
        <span class="template-label">Drug class:</span> Imidazole derivative, GABA-A receptor agonist
    </div>
    
    <div class="template-section">
        <span class="template-label">Mechanism of action:</span> 
        ‚Ä¢ Potentiates GABA-A receptor activity ‚Üí increased chloride conductance<br>
        ‚Ä¢ Minimal effects on cardiovascular system (hemodynamically neutral)<br>
        ‚Ä¢ Decreases cerebral metabolic rate and intracranial pressure<br>
        ‚Ä¢ Maintains cerebral perfusion pressure (minimal effect on MAP)<br>
        ‚Ä¢ Inhibits 11Œ≤-hydroxylase ‚Üí suppresses cortisol synthesis (dose-dependent)<br>
        ‚Ä¢ Rapid onset (30-60 seconds) due to high lipid solubility<br>
        ‚Ä¢ Short duration (3-5 minutes) due to rapid redistribution
    </div>
    
    <div class="template-section">
        <span class="template-label">Indications:</span>
        ‚Ä¢ Induction agent for RSI (especially in hemodynamically unstable patients)<br>
        ‚Ä¢ Procedural sedation for cardioversion (hemodynamically stable)<br>
        ‚Ä¢ Induction in patients with coronary artery disease, heart failure<br>
        ‚Ä¢ Patients with hypovolemia, sepsis, cardiac tamponade<br>
        ‚Ä¢ Neurosurgical patients (reduces ICP while maintaining CPP)<br>
        ‚Ä¢ Elderly patients with cardiovascular compromise<br>
        ‚Ä¢ Patients on beta-blockers, ACE inhibitors (less hypotension risk)
    </div>
    
    <div class="template-section">
        <span class="template-label">Contraindications:</span>
        ‚Ä¢ Known hypersensitivity to etomidate<br>
        ‚Ä¢ Porphyria (relative contraindication)<br>
        ‚Ä¢ Adrenal insufficiency (exacerbates adrenal suppression)<br>
        ‚Ä¢ Sepsis (relative - adrenal suppression concern, but often still used)<br>
        ‚Ä¢ Not for prolonged infusion (adrenal suppression)<br>
        ‚Ä¢ Pregnancy (Category C, limited data)<br>
        ‚Ä¢ Children (relative - more myoclonus, limited evidence in sepsis)
    </div>
    
    <div class="template-section">
        <span class="template-label">Adult dose:</span>
        ‚Ä¢ <strong class="etomidate-orange">RSI induction:</strong> 0.3 mg/kg IV (typical 20 mg for 70 kg adult)<br>
        ‚Ä¢ <strong class="etomidate-orange">Procedural sedation:</strong> 0.1-0.3 mg/kg IV<br>
        ‚Ä¢ <strong class="etomidate-orange">Elderly/debilitated:</strong> 0.2-0.3 mg/kg IV (reduce dose by 30-50%)<br>
        ‚Ä¢ <strong class="etomidate-orange">Cardioversion:</strong> 0.15-0.3 mg/kg IV<br>
        ‚Ä¢ <strong class="etomidate-orange">Single dose only</strong> - not for repeated dosing or infusion<br>
        ‚Ä¢ <strong class="etomidate-orange">Max dose:</strong> Usually 40 mg (rarely needed)
    </div>
    
    <div class="template-section">
        <span class="template-label">Pediatric dose:</span>
        ‚Ä¢ <strong class="etomidate-orange">RSI induction:</strong> 0.2-0.3 mg/kg IV<br>
        ‚Ä¢ <strong class="etomidate-orange">Procedural sedation:</strong> 0.1-0.3 mg/kg IV<br>
        ‚Ä¢ <strong class="etomidate-orange">Controversial in pediatric sepsis</strong> due to adrenal suppression concerns<br>
        ‚Ä¢ <strong class="etomidate-orange">Neonates/infants:</strong> Limited data, use with caution<br>
        ‚Ä¢ <strong class="etomidate-orange">Max pediatric dose:</strong> 20-30 mg based on weight
    </div>
    
    <div class="template-section">
        <span class="template-label">Route & preparation:</span>
        ‚Ä¢ <strong class="etomidate-orange">Routes:</strong> IV only (painful on injection)<br>
        ‚Ä¢ <strong class="etomidate-orange">Preparation:</strong> 2 mg/mL (10 mL = 20 mg, 20 mL = 40 mg)<br>
        ‚Ä¢ <strong class="etomidate-orange">For IV push:</strong> Give undiluted over 30-60 seconds<br>
        ‚Ä¢ <strong class="etomidate-orange">Pain on injection:</strong> Very common - can pretreat with lidocaine or dilute<br>
        ‚Ä¢ <strong class="etomidate-orange">Dilution:</strong> Can dilute with NS to reduce pain (but not typically done in RSI)<br>
        ‚Ä¢ <strong class="etomidate-orange">Compatibility:</strong> Compatible with most IV solutions
    </div>
    
    <div class="template-section">
        <span class="template-label">Side effects:</span>
        ‚Ä¢ Myoclonus (involuntary muscle movements) - 30-60% of patients<br>
        ‚Ä¢ Pain on injection (30-50%)<br>
        ‚Ä¢ Nausea, vomiting (30-40%, especially with movement during recovery)<br>
        ‚Ä¢ Adrenal suppression (dose-dependent, single dose suppresses 6-12 hours)<br>
        ‚Ä¢ Hiccups<br>
        ‚Ä¢ Respiratory depression (less than other induction agents)<br>
        ‚Ä¢ Thrombophlebitis
    </div>
    
    <div class="template-section">
        <span class="template-label">Adverse effects / ADR:</span>
        ‚Ä¢ Adrenal insufficiency (with repeated dosing or infusion)<br>
        ‚Ä¢ Seizures (rare, usually in epileptics)<br>
        ‚Ä¢ Anaphylaxis (rare)<br>
        ‚Ä¢ Hemolysis (with propylene glycol formulation, rare with newer lipid emulsion)<br>
        ‚Ä¢ Prolonged sedation in elderly (reduced clearance)<br>
        ‚Ä¢ Increased mortality in sepsis (controversial - single dose probably safe)<br>
        ‚Ä¢ Cardiac arrest (rare, usually with underlying cardiac disease)
    </div>
    
    <div class="template-section">
        <span class="template-label">Drug interactions:</span>
        ‚Ä¢ <strong class="etomidate-orange">Opioids/benzodiazepines:</strong> Potentiates respiratory depression<br>
        ‚Ä¢ <strong class="etomidate-orange">Fentanyl:</strong> May reduce myoclonus when given before etomidate<br>
        ‚Ä¢ <strong class="etomidate-orange">CYP3A4 inhibitors:</strong> May prolong effect (ketoconazole, erythromycin)<br>
        ‚Ä¢ <strong class="etomidate-orange">CYP3A4 inducers:</strong> May shorten effect (rifampin, carbamazepine)<br>
        ‚Ä¢ <strong class="etomidate-orange">Alcohol:</strong> Additive CNS depression<br>
        ‚Ä¢ <strong class="etomidate-orange">Theophylline:</strong> May reduce seizure threshold
    </div>
    
    <div class="template-section">
        <span class="template-label">Emergency pearls:</span>
        ‚Ä¢ <strong class="etomidate-orange">"Hemodynamically neutral":</strong> First choice for unstable patients with unknown volume status<br>
        ‚Ä¢ <strong class="etomidate-orange">Myoclonus:</strong> Not seizures - benign, self-limited, reduced by fentanyl pre-treatment<br>
        ‚Ä¢ <strong class="etomidate-orange">Adrenal suppression:</strong> Single dose suppresses cortisol for 6-12 hours - CONTROVERSIAL in sepsis<br>
        ‚Ä¢ <strong class="etomidate-orange">Sepsis controversy:</strong> Single dose probably safe, avoid repeated doses/infusions<br>
        ‚Ä¢ <strong class="etomidate-orange">Pain on injection:</strong> Pretreat with lidocaine or give through fast-flowing IV<br>
        ‚Ä¢ <strong class="etomidate-orange">Propylene glycol formulation:</strong> Older formulation causes more pain/hemolysis - lipid emulsion preferred<br>
        ‚Ä¢ <strong class="etomidate-orange">Rapid recovery:</strong> 3-5 minutes - good for brief procedures<br>
        ‚Ä¢ <strong class="etomidate-orange">Not for analgesia:</strong> No pain relief - must co-administer analgesic for painful procedures
    </div>
</div>

<!-- CHAPTER 5: DRUG 4 - SUCCINYLCHOLINE -->
<div class="page-break"></div>
<h2><span class="chapter-number">5</span> Core Drug 4: Succinylcholine</h2>

<div class="drug-template">
    <h4>SUCCINYLCHOLINE - DEPOLARIZING NEUROMUSCULAR BLOCKING AGENT</h4>
    
    <div class="template-section">
        <span class="template-label">Drug class:</span> Depolarizing neuromuscular blocking agent
    </div>
    
    <div class="template-section">
        <span class="template-label">Mechanism of action:</span> 
        ‚Ä¢ Binds nicotinic acetylcholine receptors at neuromuscular junction ‚Üí persistent depolarization<br>
        ‚Ä¢ Initial fasciculations (muscle contractions) followed by paralysis<br>
        ‚Ä¢ Phase I block: Persistent depolarization prevents further muscle contraction<br>
        ‚Ä¢ Phase II block: With high/repeated doses, becomes non-depolarizing block<br>
        ‚Ä¢ Rapid onset (30-60 seconds) due to structural similarity to acetylcholine<br>
        ‚Ä¢ Short duration (5-10 minutes) due to rapid metabolism by plasma pseudocholinesterase<br>
        ‚Ä¢ NOT reversible with neostigmine (anticholinesterases may prolong Phase II block)
    </div>
    
    <div class="template-section">
        <span class="template-label">Indications:</span>
        ‚Ä¢ Rapid Sequence Intubation (RSI) - gold standard for rapid onset paralysis<br>
        ‚Ä¢ Electroconvulsive therapy (ECT) - to prevent musculoskeletal complications<br>
        ‚Ä¢ Short surgical procedures requiring muscle relaxation<br>
        ‚Ä¢ Laryngospasm refractory to other treatments<br>
        ‚Ä¢ Emergency situations requiring rapid paralysis (traction on fetal head, laryngospasm)<br>
        ‚Ä¢ When rapid recovery of spontaneous ventilation is desired<br>
        ‚Ä¢ Patients with difficult airway where short duration is advantageous
    </div>
    
    <div class="template-section">
        <span class="template-label">Contraindications:</span>
        ‚Ä¢ Known malignant hyperthermia susceptibility (trigger agent)<br>
        ‚Ä¢ History of malignant hyperthermia in patient or family<br>
        ‚Ä¢ Major burns (>24 hours post-burn to 2 years post-healing)<br>
        ‚Ä¢ Major trauma/crush injury (>24 hours to 2 years post-injury)<br>
        ‚Ä¢ Spinal cord injury with paralysis (>24 hours to 2 years post-injury)<br>
        ‚Ä¢ Neuromuscular diseases (ALS, muscular dystrophy, myasthenia gravis)<br>
        ‚Ä¢ Hyperkalemia or conditions predisposing to hyperkalemia<br>
        ‚Ä¢ Pseudocholinesterase deficiency (prolonged paralysis)
    </div>
    
    <div class="template-section">
        <span class="template-label">Adult dose:</span>
        ‚Ä¢ <strong class="succinylcholine-red">RSI paralysis:</strong> 1-1.5 mg/kg IV (typical 100 mg for 70 kg adult)<br>
        ‚Ä¢ <strong class="succinylcholine-red">IM administration:</strong> 3-4 mg/kg IM (max 150 mg per site)<br>
        ‚Ä¢ <strong class="succinylcholine-red">Infusion for continuous paralysis:</strong> NOT recommended (risk of Phase II block)<br>
        ‚Ä¢ <strong class="succinylcholine-red">Reduced dose with pseudocholinesterase deficiency:</strong> 0.5 mg/kg<br>
        ‚Ä¢ <strong class="succinylcholine-red">Repeat doses:</strong> Avoid if possible - increases risk of Phase II block, bradycardia<br>
        ‚Ä¢ <strong class="succinylcholine-red">Max single dose:</strong> 150 mg IV
    </div>
    
    <div class="template-section">
        <span class="template-label">Pediatric dose:</span>
        ‚Ä¢ <strong class="succinylcholine-red">RSI paralysis:</strong> 1-2 mg/kg IV (higher mg/kg than adults)<br>
        ‚Ä¢ <strong class="succinylcholine-red">IM administration:</strong> 4-5 mg/kg IM (max 150 mg)<br>
        ‚Ä¢ <strong class="succinylcholine-red">Infants (<2 years):</strong> 2 mg/kg IV (higher dose due to larger volume of distribution)<br>
        ‚Ä¢ <strong class="succinylcholine-red">Neonates:</strong> 2 mg/kg IV, pre-treat with atropine 0.02 mg/kg<br>
        ‚Ä¢ <strong class="succinylcholine-red">Bradycardia risk:</strong> Pre-treat with atropine 0.02 mg/kg if <5 years or second dose<br>
        ‚Ä¢ <strong class="succinylcholine-red">Contraindications similar to adults</strong> (MH, burns, trauma, etc.)
    </div>
    
    <div class="template-section">
        <span class="template-label">Route & preparation:</span>
        ‚Ä¢ <strong class="succinylcholine-red">Routes:</strong> IV (preferred), IM, rarely subcutaneous<br>
        ‚Ä¢ <strong class="succinylcholine-red">Preparation:</strong> 20 mg/mL (10 mL = 200 mg), 50 mg/mL (10 mL = 500 mg), 100 mg/mL (10 mL = 1000 mg)<br>
        ‚Ä¢ <strong class="succinylcholine-red">For IV push:</strong> Give undiluted rapidly (over 5-10 seconds)<br>
        ‚Ä¢ <strong class="succinylcholine-red">IM administration:</strong> Deep IM injection, onset 2-3 minutes<br>
        ‚Ä¢ <strong class="succinylcholine-red">Storage:</strong> Refrigerate (2-8¬∞C), but stable at room temperature for 14 days<br>
        ‚Ä¢ <strong class="succinylcholine-red">Compatibility:</strong> Compatible with most IV solutions, acidic pH
    </div>
    
    <div class="template-section">
        <span class="template-label">Side effects:</span>
        ‚Ä¢ Fasciculations (muscle twitching) - precedes paralysis<br>
        ‚Ä¢ Postoperative myalgia (24-48 hours after administration)<br>
        ‚Ä¢ Bradycardia (especially with repeat doses, pediatric patients)<br>
        ‚Ä¢ Increased intraocular pressure (transient, 5-10 minutes)<br>
        ‚Ä¢ Increased intracranial pressure (transient)<br>
        ‚Ä¢ Hyperkalemia (0.5-1 mEq/L increase normally)<br>
        ‚Ä¢ Malignant hyperthermia (in susceptible individuals)
    </div>
    
    <div class="template-section">
        <span class="template-label">Adverse effects / ADR:</span>
        ‚Ä¢ Massive hyperkalemia and cardiac arrest (in burns, trauma, neuromuscular disease)<br>
        ‚Ä¢ Malignant hyperthermia (MH) - hypermetabolic crisis, fatal if untreated<br>
        ‚Ä¢ Prolonged paralysis (pseudocholinesterase deficiency - minutes to hours)<br>
        ‚Ä¢ Phase II block with high/repeated doses (prolonged non-depolarizing block)<br>
        ‚Ä¢ Anaphylaxis (rare)<br>
        ‚Ä¢ Cardiac arrest from profound bradycardia (especially pediatric, repeat doses)<br>
        ‚Ä¢ Masseter spasm (may progress to MH)
    </div>
    
    <div class="template-section">
        <span class="template-label">Drug interactions:</span>
        ‚Ä¢ <strong class="succinylcholine-red">Aminoglycosides, magnesium:</strong> Potentiate neuromuscular blockade<br>
        ‚Ä¢ <strong class="succinylcholine-red">Lithium:</strong> Prolongs neuromuscular blockade<br>
        ‚Ä¢ <strong class="succinylcholine-red">Cyclophosphamide, echothiophate:</strong> Inhibit pseudocholinesterase ‚Üí prolonged paralysis<br>
        ‚Ä¢ <strong class="succinylcholine-red">Beta-blockers, digoxin:</strong> Increased bradycardia risk<br>
        ‚Ä¢ <strong class="succinylcholine-red">Inhalational anesthetics:</strong> Trigger MH in susceptible individuals<br>
        ‚Ä¢ <strong class="succinylcholine-red">Acetylcholinesterase inhibitors:</strong> Prolong Phase II block
    </div>
    
    <div class="template-section">
        <span class="template-label">Emergency pearls:</span>
        ‚Ä¢ <strong class="succinylcholine-red">"Gold standard for RSI":</strong> Fastest onset (30-60 sec), shortest duration (5-10 min)<br>
        ‚Ä¢ <strong class="succinylcholine-red">Absolute contraindications:</strong> MH susceptibility, major burns (>24h), major trauma (>24h), hyperkalemia<br>
        ‚Ä¢ <strong class="succinylcholine-red">Fasciculations:</strong> Can be reduced by "defasciculating dose" of non-depolarizer (rocuronium 0.06 mg/kg)<br>
        ‚Ä¢ <strong class="succinylcholine-red">Bradycardia prevention:</strong> Pre-treat pediatric patients or if giving repeat dose with atropine<br>
        ‚Ä¢ <strong class="succinylcholine-red">Pseudocholinesterase deficiency:</strong> 1:3000 population, prolonged paralysis (hours)<br>
        ‚Ä¢ <strong class="succinylcholine-red">MH treatment:</strong> Dantrolene 2.5 mg/kg IV, repeat to max 10 mg/kg, cooling, supportive care<br>
        ‚Ä¢ <strong class="succinylcholine-red">Hyperkalemia risk:</strong> Avoid in renal failure, burns >24h old, crush injury, neuromuscular disease<br>
        ‚Ä¢ <strong class="succinylcholine-red">"Cannot intubate, cannot ventilate":</strong> Short duration allows return of spontaneous breathing
    </div>
</div>

<!-- CHAPTER 6: DRUG 5 - ROCURONIUM -->
<div class="page-break"></div>
<h2><span class="chapter-number">6</span> Core Drug 5: Rocuronium</h2>

<div class="drug-template">
    <h4>ROCURONIUM - NON-DEPOLARIZING NEUROMUSCULAR BLOCKING AGENT</h4>
    
    <div class="template-section">
        <span class="template-label">Drug class:</span> Aminosteroid, non-depolarizing neuromuscular blocking agent
    </div>
    
    <div class="template-section">
        <span class="template-label">Mechanism of action:</span> 
        ‚Ä¢ Competitive antagonist at nicotinic acetylcholine receptors at neuromuscular junction<br>
        ‚Ä¢ Prevents acetylcholine from binding ‚Üí prevents depolarization ‚Üí paralysis<br>
        ‚Ä¢ Non-depolarizing block (different mechanism from succinylcholine)<br>
        ‚Ä¢ Intermediate onset (60-90 seconds with higher doses)<br>
        ‚Ä¢ Intermediate duration (30-60 minutes with standard doses)<br>
        ‚Ä¢ Reversible with acetylcholinesterase inhibitors (neostigmine, sugammadex)<br>
        ‚Ä¢ Minimal cardiovascular effects (no histamine release at standard doses)
    </div>
    
    <div class="template-section">
        <span class="template-label">Indications:</span>
        ‚Ä¢ Rapid Sequence Intubation (alternative to succinylcholine)<br>
        ‚Ä¢ Maintenance of paralysis during surgery or mechanical ventilation<br>
        ‚Ä¢ Patients with contraindications to succinylcholine (MH, burns, trauma, hyperkalemia)<br>
        ‚Ä¢ Facilitation of tracheal intubation in operating room<br>
        ‚Ä¢ ICU paralysis for ventilator synchrony (ARDS, status asthmaticus)<br>
        ‚Ä¢ Continuous infusion for prolonged paralysis<br>
        ‚Ä¢ Defasciculation before succinylcholine (low dose: 0.06 mg/kg)
    </div>
    
    <div class="template-section">
        <span class="template-label">Contraindications:</span>
        ‚Ä¢ Known hypersensitivity to rocuronium or other aminosteroid NMBAs<br>
        ‚Ä¢ Not for use when rapid return of spontaneous ventilation is critical<br>
        ‚Ä¢ Neuromuscular diseases (may have prolonged effect)<br>
        ‚Ä¢ Severe hepatic impairment (prolonged duration)<br>
        ‚Ä¢ Not as sole agent for RSI in known/suspected difficult airway (long duration)<br>
        ‚Ä¢ Pregnancy (Category B, but generally safe)<br>
        ‚Ä¢ No absolute contraindications like succinylcholine
    </div>
    
    <div class="template-section">
        <span class="template-label">Adult dose:</span>
        ‚Ä¢ <strong class="rocuronium-blue">RSI paralysis:</strong> 1.2 mg/kg IV (typical 100 mg for 80 kg adult)<br>
        ‚Ä¢ <strong class="rocuronium-blue">Facilitating intubation:</strong> 0.6 mg/kg IV (onset 90-120 seconds)<br>
        ‚Ä¢ <strong class="rocuronium-blue">Maintenance dosing:</strong> 0.1-0.2 mg/kg IV q20-45min as needed<br>
        ‚Ä¢ <strong class="rocuronium-blue">Continuous infusion:</strong> 0.3-1.2 mg/kg/hr after loading dose<br>
        ‚Ä¢ <strong class="rocuronium-blue">Defasciculation:</strong> 0.06 mg/kg IV 3 minutes before succinylcholine<br>
        ‚Ä¢ <strong class="rocuronium-blue">Reversal:</strong> Neostigmine 0.04-0.07 mg/kg + glycopyrrolate OR Sugammadex 16 mg/kg<br>
        ‚Ä¢ <strong class="rocuronium-blue">Max single dose:</strong> 1.2 mg/kg (higher doses don't significantly speed onset)
    </div>
    
    <div class="template-section">
        <span class="template-label">Pediatric dose:</span>
        ‚Ä¢ <strong class="rocuronium-blue">RSI paralysis:</strong> 0.9-1.2 mg/kg IV<br>
        ‚Ä¢ <strong class="rocuronium-blue">Infants (1-12 months):</strong> 0.9-1.2 mg/kg IV (similar to older children)<br>
        ‚Ä¢ <strong class="rocuronium-blue">Neonates (<1 month):</strong> 0.45-0.6 mg/kg IV (reduced dose, prolonged effect)<br>
        ‚Ä¢ <strong class="rocuronium-blue">Maintenance:</strong> 0.075-0.125 mg/kg IV as needed<br>
        ‚Ä¢ <strong class="rocuronium-blue">Continuous infusion:</strong> 0.3-1.2 mg/kg/hr<br>
        ‚Ä¢ <strong class="rocuronium-blue">Duration:</strong> Longer in neonates/infants due to immature hepatic function
    </div>
    
    <div class="template-section">
        <span class="template-label">Route & preparation:</span>
        ‚Ä¢ <strong class="rocuronium-blue">Routes:</strong> IV only (not for IM use)<br>
        ‚Ä¢ <strong class="rocuronium-blue">Preparation:</strong> 10 mg/mL (5 mL = 50 mg, 10 mL = 100 mg)<br>
        ‚Ä¢ <strong class="rocuronium-blue">For IV push:</strong> Give undiluted rapidly (over 5-10 seconds)<br>
        ‚Ä¢ <strong class="rocuronium-blue">For infusion:</strong> Dilute to 0.5-1 mg/mL in NS or D5W<br>
        ‚Ä¢ <strong class="rocuronium-blue">Compatibility:</strong> Compatible with most IV solutions, alkaline pH may precipitate<br>
        ‚Ä¢ <strong class="rocuronium-blue">Storage:</strong> Room temperature, protect from light
    </div>
    
    <div class="template-section">
        <span class="template-label">Side effects:</span>
        ‚Ä¢ Tachycardia (dose-dependent, at higher doses >1.2 mg/kg)<br>
        ‚Ä¢ Hypotension (rare at standard doses)<br>
        ‚Ä¢ Bronchospasm (rare)<br>
        ‚Ä¢ Rash, flushing (rare, minimal histamine release)<br>
        ‚Ä¢ Prolonged paralysis (in hepatic/renal impairment, hypothermia)<br>
        ‚Ä¢ Residual neuromuscular blockade (inadequate reversal)
    </div>
    
    <div class="template-section">
        <span class="template-label">Adverse effects / ADR:</span>
        ‚Ä¢ Anaphylaxis (rare: 1:10,000)<br>
        ‚Ä¢ Prolonged paralysis/ICU-acquired weakness (with prolonged infusion)<br>
        ‚Ä¢ Residual paralysis post-reversal (inadequate monitoring/reversal)<br>
        ‚Ä¢ Inability to ventilate if intubation fails (long duration)<br>
        ‚Ä¢ Malignant hyperthermia (rare association, not a trigger like succinylcholine)<br>
        ‚Ä¢ Acute quadriplegic myopathy syndrome (with steroids in ICU)
    </div>
    
    <div class="template-section">
        <span class="template-label">Drug interactions:</span>
        ‚Ä¢ <strong class="rocuronium-blue">Aminoglycosides, vancomycin, magnesium:</strong> Potentiate neuromuscular blockade<br>
        ‚Ä¢ <strong class="rocuronium-blue">Inhalational anesthetics:</strong> Potentiate neuromuscular blockade<br>
        ‚Ä¢ <strong class="rocuronium-blue">Lithium, quinidine:</strong> Prolong neuromuscular blockade<br>
        ‚Ä¢ <strong class="rocuronium-blue">Carbamazepine, phenytoin:</strong> Resistance to neuromuscular blockade<br>
        ‚Ä¢ <strong class="rocuronium-blue">Cyclosporine:</strong> Prolongs neuromuscular blockade<br>
        ‚Ä¢ <strong class="rocuronium-blue">Succinylcholine:</strong> Potentiates if given shortly after
    </div>
    
    <div class="template-section">
        <span class="template-label">Emergency pearls:</span>
        ‚Ä¢ <strong class="rocuronium-blue">"Succinylcholine alternative":</strong> Use when succinylcholine contraindicated<br>
        ‚Ä¢ <strong class="rocuronium-blue">Onset with high dose (1.2 mg/kg):</strong> 60-90 seconds - almost as fast as succinylcholine<br>
        ‚Ä¢ <strong class="rocuronium-blue">Duration:</strong> 30-60 minutes - LONG compared to succinylcholine (5-10 min)<br>
        ‚Ä¢ <strong class="rocuronium-blue">Reversal options:</strong> Traditional (neostigmine + glycopyrrolate) OR Sugammadex (fast, complete)<br>
        ‚Ä¢ <strong class="rocuronium-blue">Sugammadex:</strong> 16 mg/kg reverses 1.2 mg/kg rocuronium in <3 minutes - game changer!<br>
        ‚Ä¢ <strong class="rocuronium-blue">No MH risk:</strong> Safe in malignant hyperthermia susceptible patients<br>
        ‚Ä¢ <strong class="rocuronium-blue">No hyperkalemia risk:</strong> Safe in burns, trauma, renal failure, neuromuscular disease<br>
        ‚Ä¢ <strong class="rocuronium-blue">ICU paralysis:</strong> Use with caution - daily wake-up, monitor with train-of-four, avoid with steroids
    </div>
</div>

<!-- CHAPTER 7: DRUG 6 - LIDOCAINE (AIRWAY/LOCAL) -->
<div class="page-break"></div>
<h2><span class="chapter-number">7</span> Core Drug 6: Lidocaine (Airway/Local)</h2>

<div class="drug-template">
    <h4>LIDOCAINE - LOCAL ANESTHETIC WITH MULTIPLE AIRWAY USES</h4>
    
    <div class="template-section">
        <span class="template-label">Drug class:</span> Amide local anesthetic, Class IB antiarrhythmic
    </div>
    
    <div class="template-section">
        <span class="template-label">Mechanism of action:</span> 
        ‚Ä¢ Blocks voltage-gated sodium channels ‚Üí prevents nerve depolarization and conduction<br>
        ‚Ä¢ For airway: Topical anesthesia of oropharynx, larynx, trachea<br>
        ‚Ä¢ For RSI pre-treatment: Suppresses cough reflex and attenuates hemodynamic response<br>
        ‚Ä¢ For ICP reduction: Theoretical neuroprotective effect via cerebral vasoconstriction<br>
        ‚Ä¢ Antiarrhythmic: Suppresses ventricular arrhythmias (VT, VF)<br>
        ‚Ä¢ Systemic absorption: Can cause local anesthetic systemic toxicity (LAST)<br>
        ‚Ä¢ Metabolized by liver (CYP3A4, CYP1A2), active metabolites accumulate in renal failure
    </div>
    
    <div class="template-section">
        <span class="template-label">Indications:</span>
        ‚Ä¢ Topical anesthesia for awake intubation, bronchoscopy<br>
        ‚Ä¢ RSI pre-treatment for head injury (ICP protection)<br>
        ‚Ä¢ RSI pre-treatment for reactive airway disease (bronchospasm prevention)<br>
        ‚Ä¢ Local anesthesia for procedures (laceration repair, abscess drainage, regional blocks)<br>
        ‚Ä¢ Ventricular arrhythmias (VT, VF, PVCs)<br>
        ‚Ä¢ Post-herpetic neuralgia (topical patches)<br>
        ‚Ä¢ Neuropathic pain (oral, though not first-line)<br>
        ‚Ä¢ Mucosal anesthesia (gels, sprays for urethral/rectal procedures)
    </div>
    
    <div class="template-section">
        <span class="template-label">Contraindications:</span>
        ‚Ä¢ Known hypersensitivity to lidocaine or other amide local anesthetics<br>
        ‚Ä¢ Adam-Stokes syndrome, severe heart block (without pacemaker)<br>
        ‚Ä¢ Wolff-Parkinson-White syndrome (use with caution)<br>
        ‚Ä¢ Severe hepatic impairment (reduced metabolism)<br>
        ‚Ä¢ Methemoglobinemia (especially with prilocaine, but caution with all locals)<br>
        ‚Ä¢ Injection into infected/inflamed tissue (altered absorption)<br>
        ‚Ä¢ Myasthenia gravis (may worsen weakness)
    </div>
    
    <div class="template-section">
        <span class="template-label">Adult dose:</span>
        ‚Ä¢ <strong class="lidocaine-green">RSI pre-treatment (ICP):</strong> 1.5 mg/kg IV 90 seconds before induction<br>
        ‚Ä¢ <strong class="lidocaine-green">RSI pre-treatment (asthma):</strong> 1.5 mg/kg IV 3 minutes before induction<br>
        ‚Ä¢ <strong class="lidocaine-green">Topical airway (4% spray):</strong> 4 mL maximum (160 mg)<br>
        ‚Ä¢ <strong class="lidocaine-green">Local infiltration (1%):</strong> 4.5 mg/kg maximum (7 mg/kg with epinephrine)<br>
        ‚Ä¢ <strong class="lidocaine-green">IV antiarrhythmic:</strong> 1-1.5 mg/kg bolus, then 1-4 mg/min infusion<br>
        ‚Ä¢ <strong class="lidocaine-green">Regional nerve block:</strong> Dose varies by block, use smallest effective dose<br>
        ‚Ä¢ <strong class="lidocaine-green">MAX dose (plain):</strong> 4.5 mg/kg (300 mg), (with epi): 7 mg/kg (500 mg)
    </div>
    
    <div class="template-section">
        <span class="template-label">Pediatric dose:</span>
        ‚Ä¢ <strong class="lidocaine-green">RSI pre-treatment:</strong> 1.5 mg/kg IV (same as adults)<br>
        ‚Ä¢ <strong class="lidocaine-green">Topical airway:</strong> 3 mg/kg maximum (4% solution)<br>
        ‚Ä¢ <strong class="lidocaine-green">Local infiltration:</strong> 3-5 mg/kg maximum (with/without epinephrine)<br>
        ‚Ä¢ <strong class="lidocaine-green">IV antiarrhythmic:</strong> 1 mg/kg bolus, may repeat √ó2, then 20-50 mcg/kg/min infusion<br>
        ‚Ä¢ <strong class="lidocaine-green">Neonates:</strong> Reduced doses, consult specialist (reduced metabolism)<br>
        ‚Ä¢ <strong class="lidocaine-green">ALWAYS calculate mg/kg:</strong> Critical to avoid toxicity in children
    </div>
    
    <div class="template-section">
        <span class="template-label">Route & preparation:</span>
        ‚Ä¢ <strong class="lidocaine-green">Routes:</strong> IV, topical, infiltration, regional block, endotracheal, intra-articular<br>
        ‚Ä¢ <strong class="lidocaine-green">Concentrations:</strong> 0.5%, 1%, 2% for injection; 4% for topical; 5% ointment; 10% spray<br>
        ‚Ä¢ <strong class="lidocaine-green">For IV push:</strong> Give undiluted over 1-2 minutes<br>
        ‚Ä¢ <strong class="lidocaine-green">For infusion:</strong> 1-2 g in 250-500 mL D5W (4-8 mg/mL)<br>
        ‚Ä¢ <strong class="lidocaine-green">Topical airway:</strong> Use mucosal atomizer device (MAD) for spray<br>
        ‚Ä¢ <strong class="lidocaine-green">With epinephrine:</strong> 1:100,000 or 1:200,000 - reduces absorption, prolongs duration
    </div>
    
    <div class="template-section">
        <span class="template-label">Side effects:</span>
        ‚Ä¢ CNS: Lightheadedness, drowsiness, tinnitus, perioral tingling<br>
        ‚Ä¢ Cardiovascular: Hypotension, bradycardia (at high systemic levels)<br>
        ‚Ä¢ Allergic: Rash, urticaria (rare with amides)<br>
        ‚Ä¢ Methemoglobinemia (with high doses, especially in infants)<br>
        ‚Ä¢ Transient neurological symptoms (with spinal anesthesia)<br>
        ‚Ä¢ Pain on injection (burning sensation)
    </div>
    
    <div class="template-section">
        <span class="template-label">Adverse effects / ADR:</span>
        ‚Ä¢ Local Anesthetic Systemic Toxicity (LAST) - seizures, cardiovascular collapse<br>
        ‚Ä¢ Anaphylaxis (rare with amides, more common with esters)<br>
        ‚Ä¢ Cardiac arrest (from profound bradycardia, asystole)<br>
        ‚Ä¢ Methemoglobinemia requiring methylene blue<br>
        ‚Ä¢ Neurological injury (from spinal/epidural injection)<br>
        ‚Ä¢ Tissue necrosis (with epinephrine in end-arterial areas: fingers, toes, penis, ears)<br>
        ‚Ä¢ Chondrolysis (with intra-articular infusion)
    </div>
    
    <div class="template-section">
        <span class="template-label">Drug interactions:</span>
        ‚Ä¢ <strong class="lidocaine-green">Beta-blockers:</strong> Increased lidocaine levels (reduced hepatic blood flow)<br>
        ‚Ä¢ <strong class="lidocaine-green">CYP3A4 inhibitors:</strong> Increased lidocaine levels (amiodarone, cimetidine, fluconazole)<br>
        ‚Ä¢ <strong class="lidocaine-green">Other local anesthetics:</strong> Additive toxicity<br>
        ‚Ä¢ <strong class="lidocaine-green">Succinylcholine:</strong> Prolongs neuromuscular blockade<br>
        ‚Ä¢ <strong class="lidocaine-green">Antiarrhythmics:</strong> Additive cardiac effects (Class I agents)<br>
        ‚Ä¢ <strong class="lidocaine-green">MAOIs, TCAs:</strong> Potentiate pressor effect of epinephrine in local anesthetics
    </div>
    
    <div class="template-section">
        <span class="template-label">Emergency pearls:</span>
        ‚Ä¢ <strong class="lidocaine-green">"LAST" - Local Anesthetic Systemic Toxicity:</strong> CNS symptoms first (tingling, seizures), then cardiac (CV collapse)<br>
        ‚Ä¢ <strong class="lidocaine-green">LAST treatment:</strong> 20% Lipid Emulsion 1.5 mL/kg bolus, then 0.25 mL/kg/min infusion, ACLS<br>
        ‚Ä¢ <strong class="lidocaine-green">Maximum doses:</strong> 4.5 mg/kg plain, 7 mg/kg with epinephrine - CALCULATE mg/kg!<br>
        ‚Ä¢ <strong class="lidocaine-green">RSI pre-treatment timing:</strong> ICP - 90 sec before induction; Asthma - 3 min before induction<br>
        ‚Ä¢ <strong class="lidocaine-green">Topical airway:</strong> Wait 3-5 minutes after spray for full effect, use <4 mL of 4% (160 mg)<br>
        ‚Ä¢ <strong class="lidocaine-green">With epinephrine:</strong> NEVER use in end-arterial areas (fingers, toes, penis, ears, nose tip)<br>
        ‚Ä¢ <strong class="lidocaine-green">Pediatric warning:</strong> More susceptible to LAST - use lowest effective dose<br>
        ‚Ä¢ <strong class="lidocaine-green">IV antiarrhythmic:</strong> Half-life increases with infusion duration - monitor for toxicity
    </div>
</div>

<div class="local-anesthetic-box">
    <strong>üíâ LOCAL ANESTHETIC SYSTEMIC TOXICITY (LAST) MANAGEMENT:</strong><br>
    <br>
    <strong>EARLY SIGNS (CNS):</strong><br>
    ‚Ä¢ Perioral tingling, metallic taste<br>
    ‚Ä¢ Tinnitus, dizziness, confusion<br>
    ‚Ä¢ Visual disturbances, slurred speech<br>
    ‚Ä¢ Muscle twitching, seizures<br>
    <br>
    <strong>LATE SIGNS (CARDIAC):</strong><br>
    ‚Ä¢ Hypotension, bradycardia<br>
    ‚Ä¢ Ventricular arrhythmias (VT, VF)<br>
    ‚Ä¢ Asystole, cardiovascular collapse<br>
    <br>
    <strong>TREATMENT:</strong><br>
    1. <strong>Stop injection</strong> immediately<br>
    2. <strong>Call for help</strong> and lipid emulsion<br>
    3. <strong>Airway management</strong> (may need intubation)<br>
    4. <strong>Seizure control:</strong> Benzodiazepines (midazolam)<br>
    5. <strong>ACLS protocols</strong> (avoid vasopressin, calcium channel blockers, beta-blockers)<br>
    6. <strong>20% Lipid Emulsion:</strong> 1.5 mL/kg bolus, then 0.25 mL/kg/min infusion<br>
    7. <strong>Consider cardiopulmonary bypass</strong> if available
</div>

<!-- CHAPTER 8: DIFFICULT AIRWAY MANAGEMENT -->
<div class="page-break"></div>
<h2><span class="chapter-number">8</span> Difficult Airway Management</h2>

<h3>8.1 Pharmacological Adjuncts for Difficult Airway</h3>

<table class="comparison-table">
    <thead>
        <tr>
            <th style="width: 20%;">Scenario</th>
            <th>Pharmacological Strategy</th>
            <th>Drug Choices</th>
            <th>Special Considerations</th>
        </tr>
    </thead>
    <tbody>
        <tr>
            <td><strong>Anticipated difficult airway</strong><br>(awake intubation)</td>
            <td>Topical anesthesia + mild sedation<br>"Awake look" with bronchoscope</td>
            <td>Lidocaine 4% spray, nebulized lidocaine<br>Midazolam 1-2 mg IV, fentanyl 50-100 mcg IV</td>
            <td>Maintain spontaneous ventilation<br>Have surgical airway equipment ready</td>
        </tr>
        <tr>
            <td><strong>Unanticipated difficult airway</strong><br>(failed intubation after RSI)</td>
            <td>Maintain oxygenation<br>Allow return of spontaneous ventilation</td>
            <td>Succinylcholine preferred (short duration)<br>If rocuronium given, consider sugammadex</td>
            <td>Call for help early<br>Follow difficult airway algorithm</td>
        </tr>
        <tr>
            <td><strong>Cannot intubate, cannot ventilate (CICO)</strong></td>
            <td>Emergency surgical airway<br>Reverse paralysis if possible</td>
            <td>Sugammadex 16 mg/kg for rocuronium<br>No reversal for succinylcholine</td>
            <td>Time critical - proceed to cricothyrotomy within minutes</td>
        </tr>
        <tr>
            <td><strong>Agitated/combative patient needing intubation</strong></td>
            <td>Rapid sedation without paralysis initially<br>"Delayed sequence intubation"</td>
            <td>Ketamine 1-2 mg/kg IV/IM<br>Midazolam 2-5 mg IV</td>
            <td>Maintain spontaneous ventilation<br>Paralyze only when oxygenation assured</td>
        </tr>
        <tr>
            <td><strong>Severe asthma/status asthmaticus</strong></td>
            <td>Ketamine induction<br>Avoid histamine-releasing agents</td>
            <td>Ketamine 1-2 mg/kg IV<br>Rocuronium 1.2 mg/kg IV (not succinylcholine)</td>
            <td>Permissive hypercapnia<br>Low respiratory rate, long expiratory time</td>
        </tr>
        <tr>
            <td><strong>Severe head injury with ‚ÜëICP</strong></td>
            <td>Lidocaine + fentanyl pre-treatment<br>Etomidate or propofol induction</td>
            <td>Lidocaine 1.5 mg/kg IV, fentanyl 1-3 mcg/kg<br>Etomidate 0.3 mg/kg or propofol 1-2 mg/kg</td>
            <td>Avoid ketamine (‚ÜëICP), succinylcholine (‚ÜëICP)<br>Maintain CPP >60 mmHg</td>
        </tr>
    </tbody>
</table>

<h3>8.2 Neuromuscular Blockade Monitoring & Reversal</h3>

<div class="neuromuscular-box">
    <strong>üß† MONITORING NEUROMUSCULAR BLOCKADE:</strong><br>
    <br>
    <strong>TRAIN-OF-FOUR (TOF) MONITORING:</strong><br>
    ‚Ä¢ 4 supramaximal stimuli at 2 Hz (0.5 sec apart)<br>
    ‚Ä¢ Count number of twitches: 4/4 = minimal blockade, 0/4 = complete blockade<br>
    ‚Ä¢ Useful for determining depth of blockade and timing of reversal<br>
    <br>
    <strong>REVERSAL AGENTS:</strong><br>
    1. <strong class="rocuronium-blue">Traditional (Neostigmine + Glycopyrrolate):</strong><br>
       ‚Ä¢ Neostigmine 0.04-0.07 mg/kg (max 5 mg)<br>
       ‚Ä¢ Glycopyrrolate 0.2 mg per 1 mg neostigmine<br>
       ‚Ä¢ Wait for at least 1-2 twitches before reversal<br>
       ‚Ä¢ Onset 5-10 minutes, may not reverse deep blockade<br>
    <br>
    2. <strong class="rocuronium-blue">Sugammadex (Bridion¬Æ):</strong><br>
       ‚Ä¢ Cyclodextrin that encapsulates rocuronium/vecuronium<br>
       ‚Ä¢ Dose: 16 mg/kg for 1.2 mg/kg rocuronium, 4 mg/kg for minimal blockade<br>
       ‚Ä¢ Works in <3 minutes, even with deep blockade<br>
       ‚Ä¢ Expensive (~$100 per vial) but game-changing<br>
       ‚Ä¢ No anticholinergic side effects
</div>

<!-- CHAPTER 9: PROCEDURAL SEDATION & ANALGESIA (PSA) -->
<div class="page-break"></div>
<h2><span class="chapter-number">9</span> Procedural Sedation & Analgesia (PSA)</h2>

<div class="sedation-box">
    <h3>9.1 Common PSA Combinations</h3>
    
    <strong>MINIMAL SEDATION (ANXIOLYSIS):</strong><br>
    ‚Ä¢ Patient responds normally to verbal commands<br>
    ‚Ä¢ Drugs: Midazolam 1-2 mg IV, titrated to effect<br>
    ‚Ä¢ Procedures: Minor procedures, anxiety reduction<br>
    <br>
    <strong>MODERATE SEDATION ("CONSCIOUS SEDATION"):</strong><br>
    ‚Ä¢ Purposeful response to verbal/tactile stimulation<br>
    ‚Ä¢ Combinations:<br>
    &nbsp;&nbsp;‚Ä¢ <strong class="ketamine-purple">Ketamine 0.5-1 mg/kg</strong> + Midazolam 0.02-0.04 mg/kg<br>
    &nbsp;&nbsp;‚Ä¢ <strong class="propofol-white">Propofol 0.5-1 mg/kg</strong> + Fentanyl 1-2 mcg/kg<br>
    &nbsp;&nbsp;‚Ä¢ <strong class="lidocaine-green">Fentanyl 1-2 mcg/kg</strong> + Midazolam 0.02-0.05 mg/kg<br>
    ‚Ä¢ Procedures: Fracture reduction, abscess drainage, cardioversion<br>
    <br>
    <strong>DEEP SEDATION:</strong><br>
    ‚Ä¢ Purposeful response after repeated/painful stimulation<br>
    ‚Ä¢ Drugs: Higher doses of above combinations<br>
    ‚Ä¢ Requires advanced airway skills present<br>
    ‚Ä¢ Procedures: Complex reductions, pediatric imaging<br>
    <br>
    <strong>DISSOCIATIVE SEDATION (KETAMINE):</strong><br>
    ‚Ä¢ Trance-like state, maintains airway reflexes<br>
    ‚Ä¢ <strong class="ketamine-purple">Ketamine 1-2 mg/kg IV</strong> or <strong class="ketamine-purple">4-5 mg/kg IM</strong><br>
    ‚Ä¢ Pre-treat with atropine (secretions) and midazolam (emergence reactions)<br>
    ‚Ä¢ Ideal for pediatric procedures, agitated patients<br>
</div>

<h3>9.2 Monitoring During PSA</h3>

<ol>
    <li><strong>Pre-procedure:</strong>
        <ul class="sub-list">
            <li>NPO status (if elective): 2h clear liquids, 6h light meal, 8h heavy meal</li>
            <li>Airway assessment (Mallampati, thyromental distance, neck mobility)</li>
            <li>ASA classification, comorbidities, allergies</li>
            <li>Informed consent (risks: hypoxia, apnea, aspiration, death)</li>
        </ul>
    </li>
    <li><strong>During procedure:</strong>
        <ul class="sub-list">
            <li>Continuous pulse oximetry and ECG</li>
            <li>Blood pressure every 3-5 minutes</li>
            <li>Respiratory rate continuously</li>
            <li>Capnography if available (early detection of apnea)</li>
            <li>Level of sedation (modified Ramsay scale)</li>
            <li>Dedicated observer (not performing procedure)</li>
        </ul>
    </li>
    <li><strong>Post-procedure:</strong>
        <ul class="sub-list">
            <li>Recovery until discharge criteria met (Aldrete score ‚â•9)</li>
            <li>Monitoring for 30-120 minutes depending on drugs used</li>
            <li>Discharge instructions (no driving, no signing legal documents for 24h)</li>
            <li>Follow-up for potential complications</li>
        </ul>
    </li>
</ol>

<!-- APPENDIX: QUICK REFERENCE GUIDES -->
<div class="page-break"></div>
<h2>Appendix: Quick Reference Guides</h2>

<h3>Emergency Airway Drug Dosing Quick Guide</h3>

<table class="comparison-table">
    <thead>
        <tr>
            <th>Drug</th>
            <th>Adult RSI Dose</th>
            <th>Pediatric RSI Dose</th>
            <th>Onset</th>
            <th>Duration</th>
            <th>Key Features</th>
        </tr>
    </thead>
    <tbody>
        <tr>
            <td><strong>Ketamine</strong></td>
            <td>1-2 mg/kg IV</td>
            <td>1-2 mg/kg IV</td>
            <td>30-60 sec</td>
            <td>10-20 min</td>
            <td>Bronchodilator, maintains BP, emergence reactions</td>
        </tr>
        <tr>
            <td><strong>Propofol</strong></td>
            <td>1.5-2.5 mg/kg IV</td>
            <td>2-3 mg/kg IV</td>
            <td>30-60 sec</td>
            <td>5-10 min</td>
            <td>Hypotension risk, antiemetic, no analgesia</td>
        </tr>
        <tr>
            <td><strong>Etomidate</strong></td>
            <td>0.3 mg/kg IV</td>
            <td>0.2-0.3 mg/kg IV</td>
            <td>30-60 sec</td>
            <td>3-5 min</td>
            <td>Hemodynamically neutral, myoclonus, adrenal suppression</td>
        </tr>
        <tr>
            <td><strong>Succinylcholine</strong></td>
            <td>1-1.5 mg/kg IV</td>
            <td>1-2 mg/kg IV</td>
            <td>30-60 sec</td>
            <td>5-10 min</td>
            <td>Fastest onset, MH trigger, hyperkalemia risk</td>
        </tr>
        <tr>
            <td><strong>Rocuronium</strong></td>
            <td>1.2 mg/kg IV</td>
            <td>0.9-1.2 mg/kg IV</td>
            <td>60-90 sec</td>
            <td>30-60 min</td>
            <td>Succinylcholine alternative, reversible with sugammadex</td>
        </tr>
        <tr>
            <td><strong>Lidocaine (pre-tx)</strong></td>
            <td>1.5 mg/kg IV</td>
            <td>1.5 mg/kg IV</td>
            <td>1-2 min</td>
            <td>20-30 min</td>
            <td>ICP/asthma pre-treatment, topical airway anesthesia</td>
        </tr>
    </tbody>
</table>

<h3>Rapid Sequence Intubation Checklist</h3>

<div class="clinical-pearl">
    <strong>üìã RSI PREPARATION CHECKLIST:</strong><br>
    <br>
    <strong>EQUIPMENT (AT THE BEDSIDE):</strong><br>
    ‚Ä¢ Working suction with Yankauer tip<br>
    ‚Ä¢ Oxygen source with bag-valve-mask (BVM)<br>
    ‚Ä¢ Laryngoscope handles (x2) and blades (Mac 3-4, Miller 2-3)<br>
    ‚Ä¢ Endotracheal tubes (6.0-8.0, plus one size up/down)<br>
    ‚Ä¢ Stylet, 10 mL syringe, tube holder<br>
    ‚Ä¢ End-tidal CO‚ÇÇ detector (colorimetric or capnography)<br>
    ‚Ä¢ Rescue devices (LMA, video laryngoscope, bougie, surgical airway kit)<br>
    <br>
    <strong>DRUGS (PRE-DRAWN AND LABELED):</strong><br>
    1. Induction agent (ketamine/etomidate/propofol)<br>
    2. Neuromuscular blocker (succinylcholine/rocuronium)<br>
    3. Sedative for post-intubation (midazolam/propofol)<br>
    4. Analgesic for post-intubation (fentanyl)<br>
    5. Push-dose vasopressor (ephedrine/phenylephrine)<br>
    6. Reversal agents (naloxone/flumazenil/sugammadex if using rocuronium)<br>
    <br>
    <strong>PERSONNEL:</strong><br>
    ‚Ä¢ Intubator (most experienced available)<br>
    ‚Ä¢ Airway assistant (to hand equipment, apply cricoid pressure)<br>
    ‚Ä¢ Drug administrator (dedicated to giving medications)<br>
    ‚Ä¢ Monitor watcher (dedicated to vital signs)<br>
    ‚Ä¢ Recorder (document times, drugs, attempts)
</div>

<h3>Local Anesthetic Maximum Doses</h3>
<table class="comparison-table">
    <thead>
        <tr>
            <th>Local Anesthetic</th>
            <th>Plain (mg/kg)</th>
            <th>With Epinephrine (mg/kg)</th>
            <th>Typical 70kg Adult Max</th>
            <th>Onset</th>
            <th>Duration</th>
        </tr>
    </thead>
    <tbody>
        <tr>
            <td><strong>Lidocaine</strong></td>
            <td>4.5 mg/kg</td>
            <td>7 mg/kg</td>
            <td>300 mg plain, 500 mg with epi</td>
            <td>Fast (2-5 min)</td>
            <td>1-2 hours</td>
        </tr>
        <tr>
            <td><strong>Bupivacaine</strong></td>
            <td>2 mg/kg</td>
            <td>2.5 mg/kg</td>
            <td>140 mg plain, 175 mg with epi</td>
            <td>Slow (5-10 min)</td>
            <td>4-8 hours</td>
        </tr>
        <tr>
            <td><strong>Ropivacaine</strong></td>
            <td>3 mg/kg</td>
            <td>Not typically used</td>
            <td>210 mg</td>
            <td>Intermediate</td>
            <td>3-6 hours</td>
        </tr>
        <tr>
            <td><strong>Mepivacaine</strong></td>
            <td>4.5 mg/kg</td>
            <td>7 mg/kg</td>
            <td>300 mg plain, 500 mg with epi</td>
            <td>Fast</td>
            <td>2-3 hours</td>
        </tr>
    </tbody>
</table>

<div class="footer-note">
    <strong>¬© Emergency Medicine Education Team | Confidential Educational Material</strong><br>
    This document is for educational purposes only. Always follow local protocols and guidelines.<br>
    Medications and doses may vary by institution. Verify all information before clinical application.<br>
    Version 1.0 | Last updated: [Current Date] | Module 9 of 10
</div>

</body>
</html>